Truncated memapsin 2 compositions and treatments
AssigneeOklahoma Medical Research Foundation
InventorsWan Pin CHANG, Deborah Downs, Jordan J.N. Tang
Life of this patent
Estimating the term…
Abstract
The present invention provides novel methods of reducing memapsin 2 β-secretase activity in a subject, decreasing levels of β-amyloid peptide in the brain of a subject, treating Alzheimer's disease and/or reducing the size and/or number of β-amyloid plaques in the brain of a subject. The methods may include the step of administering an effective amount of truncated memapsin 2 protein, anti-truncated memapsin 2 antibody, and/or nucleic acid encoding a truncated memapsin 2 protein or anti-truncated memapsin 2 antibody. The present invention also provides related pharmaceutical compositions and uses thereof.
Claims18
A method of reducing memapsin 2 β-secretase activity to treat a disease associated with memapsin 2 β-secretase activity in a subject in need of such treatment, the method comprising administering to said subject an effective amount of a truncated memapsin 2 protein, and wherein said truncated memapsin 2 protein consists of amino acids 63-454 of FIG. 4, optionally containing at least one conservative amino acid substitution.
5-9. (canceled)
A method of decreasing levels of β-amyloid peptide in the brain of a subject, said method comprising administering to said subject an effective amount of a truncated memapsin 2 protein, and wherein said truncated memapsin 2 protein consists of amino acids 63-454 of FIG. 4, optionally containing at least one conservative amino acid substitution, and said truncated memapsin 2 protein reduces memapsin 2 β-secretase activity in said subject.
A method of reducing the size or number of β-amyloid plaques in the brain of said subject, said method comprising administering to said subject an effective amount of a truncated memapsin 2 protein, and wherein said truncated memapsin 2 protein consists of amino acids 63-454 of FIG. 4, optionally containing at least one conservative amino acid substitution, and said truncated memapsin 2 protein reduces memapsin 2 β-secretase activity in said subject.
A method of treating Alzheimer's disease in a patient in need of such treatment, said method comprising administering to said subject an effective amount of a truncated memapsin 2 protein, and wherein said truncated memapsin 2 protein consists of amino acids 63-454 of FIG. 4, optionally containing at least one conservative amino acid substitution, and said truncated memapsin 2 protein reduces memapsin 2 β-secretase activity in said subject.
An antibody specifically immunoreactive with a truncated memapsin 2 protein, and wherein said truncated memapsin 2 protein consists of amino acids 63-454 of FIG. 4, optionally containing at least one conservative amino acid substitution, and said antibody reduces memapsin 2 β-secretase activity.
A pharmaceutical composition comprising a truncated memapsin 2 and a pharmaceutically acceptable adjuvant, wherein said truncated memapsin 2 protein consists of amino acids 63-454 of FIG. 4, optionally containing at least one conservative amino acid substitution.
A pharmaceutical composition comprising a nucleic acid encoding a truncated memapsin 2 and a pharmaceutically acceptable excipient, wherein said truncated memapsin 2 protein consists of amino acids 63-454 of FIG. 4, optionally containing at least one conservative amino acid substitution.
An antibody specifically immunoreactive with a truncated memapsin 2 protein, and wherein said truncated memapsin 2 protein consists of amino acids 63-454 of FIG. 4, optionally containing at least one conservative amino acid substitution, and said antibody reduces Aβ production.
Dependencies are inferred from the claim text.